Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
$51.61 Million in Sales Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter - Opera News
HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
PUMA BIOTECHNOLOGY: FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | FDA Health News
Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up - Market Exclusive
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Where Will Puma Biotechnology Inc (PBYI) Stock Go Next After It Is Lower By 3.91% in a Week?
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict | Los Angeles Business Journal
Puma Biotechnology, Inc. 2020 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
Puma Biotechnology
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
